人才培养

杨 烨

邮箱 yangye876@sina.com

职称 教授 博士生导师

教育经历

2008.09-2012.06     中国药科大学,微生物与生化药学专业,博士

2006.09-2008.06     中国药科大学,微生物与生化药学专业,硕士

2002.09-2006.06     中国药科大学,生命科学与技术基地班,本科

工作经历

2015.10-至今 南京中医药大学医学与生命科学学院药理系,教授

2012.10-2015.06     美国爱荷华大学医学院,博士后

2012.06-2012.10     美国犹他大学医学院,博士后

2009.05-2012.06     美国犹他大学医学院,访问学者

社会和学术团体服务

1、会员:中国药理学会生化与分子药理学专业委员会青年委员、江苏省中医药学会理事、美国血液病协会会员(ID 1069914)。

2、杂志编辑:《El Mednifico Journal》编委、《药物生物技术》编委

3、杂志审稿人: Oncotarget (IF: 6.359);Cancer Letter (IF: 5.621);International Journal of Cancer (IF: 5.085);Carbohydrate Polymers (IF: 4.074);Virchows Archiv (IF: 2.621);Leukemia Research (IF: 2.351);Cancer Gene Therapy (IF: 2.461);BioMed Research International (IF: 1.579)

科学研究

研究方向

多发性骨髓瘤药理学、肿瘤干细胞及耐药研究

主持科研课题

1.  2016年度国家重点研发计划“精准医学研究”项目(2016YFC0905900)子课题,2016-2020100万,在研,主持

2.  2016年江苏省杰出青年基金,2016/07-2019/0699万,在研,主持

3.  国家自然科学基金面上项目,81670200BUB1B调控多发性骨髓瘤细胞增殖和耐药作用及机制研究,57万,在研,主持

4.  国家自然科学基金青年项目,81500166BTK引发多发性骨髓瘤耐药性研究,2016/01-2018/1218万元,在研,主持

5.  中医学优势学科二期建设项目子课题,2016-201760万元,在研,主持

人才计划

1.  2015江苏省特聘教授项目,2016/012018/12200万元,在研, 主持

2.  2016年江苏省六大人才高峰(A)2016-201915万元,在研,主持

科研奖励

第十五届江苏省青年科技奖暨“十大青年科技之星”

主要科研成果(*通讯作者

1.      Zhou W, Yang Y(共同第一), Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D, Tricot G and Zhan F. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer cell. 2013; 23(1):48-62. IF23.523

2. Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H, Zhou W, Zhou Y, Das S, Gu Z, Levasseur D, Zhan F and Tricot G. RARalpha2 expression confers myeloma stem cell features. Blood. 2013; 122(8):1437-1447. IF10.452

3. Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G and Zhan F. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer research. 2015; 75(3):594-604. IF9.329

4. Gu C, Yang Y(共同第一), Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F and Janz S. FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia. 2016; 30(4):873-882. IF10.431

5.      Zhou W, Yang Y(共同第一), Gu Z, Wang H, Xia J, Wu X, Zhan X, Levasseur D, Zhou Y, Janz S, Tricot G, Shi J and Zhan F. ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia. 2014; 28(5):1155-1158. IF10.431

6. Gu C, Feng L, Peng H, Yang H, Feng Z and Yang Y (通讯作者). MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment. Oncotarget. 2016; 7(4):4559-4569. IF:6.359

7. Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G and Zhan F. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget. 2014; 5(23):11986-11997. IF:6.359

8.      Gu C, Yang Y(共同第一), Xiang H, Li S, Liang L, Sui H, Zhan L and Lu X. Deciphering Bacterial Community changes in Zucker diabetic fatty rats based on 16S rRNA gene sequences analysis. Oncotarget. 2016. (已接收) IF6.359

9.      Li F, Yang Y, Jin F, Dehoedt C, Rao J, Zhou Y, Li P, Yang G, Wang M, Zhang R and Yang Y (通讯作者). Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: a retrospective study of increasing awareness of a disease from a single-center in China. Orphanet J Rare Dis. 2015; 10:20. IF3.358

10.    Wang X, Yang Y (共同第一), Jia H, Jia W, Miller S, Bowman B, Feng J and Zhan F. Peptide Decoration of Nanovehicles to Achieve Active Targeting and Pathology-Responsive Cellular Uptake for Bone Metastasis Chemotherapy. Biomater Sci. 2014; 2(7):961-971. IF3.831

ADDIN EN.REFLIST 11. Yang Y (通讯作者), Gu C, Luo C, Li F and Wang M. BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis. Med Oncol. 2015; 32(3):81. IF2.634

12.    Veitonmaki N, Hansson M, Zhan F, Sundberg A, Lofstedt T, Ljungars A, Li ZC, Martinsson-Niskanen T, Zeng M, Yang Y, Danielsson L, Kovacek M, Lundqvist A, Martensson L, Teige I, Tricot G, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013; 23(4):502-515. IF23.523

13.    Gu Z, Wang H, Xia J, Yang Y, Jin Z, Xu H, Shi J, De Domenico I, Tricot G and Zhan F. Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation. Cancer Res. 2015; 75(11):2211-2221. IF9.329

14.    Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, Tricot G and Zhan F. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma. Clinical cancer research. 2015; 21(24):5532-5542. IF8.722

15.    Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G and Zhan F. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget. 2010; 1(1):22-33. IF6.359

16.    Li P, Huang P, Yang Y, Hao M, Peng H and Li F. Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS). Clinical reviews in allergy & immunology. 2016; 50(1):55-63. IF:5.463

17.    Li F, Xu Y, Deng P, Yang Y, Sui W, Jin F, Hao M, Li Z, Zang M, Zhou D, Gu Z, Ru K, Wang J, Cheng T and Qiu L. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma. Oncotarget. 2015; 6(11):9434-9444. IF:6.359

18.    Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, Li F, Qi F, Zhang Y, Yang Y, Zhan F and Qiu L. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2015; 136(8):1835-1844. IF5.085

19.    Zangari M, Berno T, Yang Y, Zeng M, Xu H, Pappas L, Tricot G, Kamalakar A, Yoon D and Suva LJ. Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. Bone. 2014; 61:39-43. IF3.973

20.    Liu J, Gu Z, Yang Y, Wendlandt E and Xu H. A subset of CD20(+) MM patients without the t(11;14) are associated with poor prognosis and a link to aberrant expression of Wnt signaling. Hematol Oncol. 2014; 32(4):215-217. IF3.084

21.    Gu Z, Zhou W, Huang J, Yang Y, Wendlandt E, Xu H, He X, Tricot G and Zhan F. Nek2 is a novel regulator of B cell development and immunological response. BioMed research international. 2014:621082. IF1.579

22. 杨烨, 顾春艳, 陆美龄 and 王旻. CAYl0404 靶向干预 Wnt/β-catenin 信号通路对多发性骨髓瘤干细胞清除作用的研究 [J]. 药物生物技术. 2013; 2:008.

教育教学

执教课程

《药理学》

主要教学论著和成果